List of Tables
Table 1. Global VEGF Inhibitors Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global VEGF Inhibitors Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global VEGF Inhibitors Market Competitive Situation by Manufacturers in 2025
Table 4. Global VEGF Inhibitors Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global VEGF Inhibitors Sales Market Share by Manufacturers (2021–2026)
Table 6. Global VEGF Inhibitors Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global VEGF Inhibitors Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market VEGF Inhibitors Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of VEGF Inhibitors, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of VEGF Inhibitors, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of VEGF Inhibitors, Product Types and Applications
Table 12. Global Key Manufacturers of VEGF Inhibitors, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global VEGF Inhibitors Companies by Tier (Tier 1, Tier 2, Tier 3), based on VEGF Inhibitors Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global VEGF Inhibitors Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global VEGF Inhibitors Sales by Region (K Units), 2021–2026
Table 18. Global VEGF Inhibitors Sales Market Share by Region (2021–2026)
Table 19. Global VEGF Inhibitors Sales by Region (K Units), 2027–2032
Table 20. Global VEGF Inhibitors Sales Market Share by Region (2027–2032)
Table 21. Global VEGF Inhibitors Revenue by Region (US$ Million), 2021–2026
Table 22. Global VEGF Inhibitors Revenue Market Share by Region (2021–2026)
Table 23. Global VEGF Inhibitors Revenue by Region (US$ Million), 2027–2032
Table 24. Global VEGF Inhibitors Revenue Market Share by Region (2027–2032)
Table 25. North America VEGF Inhibitors Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America VEGF Inhibitors Sales by Country (K Units), 2021–2026
Table 27. North America VEGF Inhibitors Sales by Country (K Units), 2027–2032
Table 28. North America VEGF Inhibitors Revenue by Country (US$ Million), 2021–2026
Table 29. North America VEGF Inhibitors Revenue by Country (US$ Million), 2027–2032
Table 30. Europe VEGF Inhibitors Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe VEGF Inhibitors Sales by Country (K Units), 2021–2026
Table 32. Europe VEGF Inhibitors Sales by Country (K Units), 2027–2032
Table 33. Europe VEGF Inhibitors Revenue by Country (US$ Million), 2021–2026
Table 34. Europe VEGF Inhibitors Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific VEGF Inhibitors Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific VEGF Inhibitors Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific VEGF Inhibitors Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific VEGF Inhibitors Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific VEGF Inhibitors Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America VEGF Inhibitors Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America VEGF Inhibitors Sales by Country (K Units), 2021–2026
Table 42. Latin America VEGF Inhibitors Sales by Country (K Units), 2027–2032
Table 43. Latin America VEGF Inhibitors Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America VEGF Inhibitors Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa VEGF Inhibitors Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa VEGF Inhibitors Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa VEGF Inhibitors Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa VEGF Inhibitors Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa VEGF Inhibitors Revenue by Country (US$ Million), 2027–2032
Table 50. Global VEGF Inhibitors Sales (K Units) by Type (2021–2026)
Table 51. Global VEGF Inhibitors Sales (K Units) by Type (2027–2032)
Table 52. Global VEGF Inhibitors Sales Market Share by Type (2021–2026)
Table 53. Global VEGF Inhibitors Sales Market Share by Type (2027–2032)
Table 54. Global VEGF Inhibitors Revenue (US$ Million) by Type (2021–2026)
Table 55. Global VEGF Inhibitors Revenue (US$ Million) by Type (2027–2032)
Table 56. Global VEGF Inhibitors Revenue Market Share by Type (2021–2026)
Table 57. Global VEGF Inhibitors Revenue Market Share by Type (2027–2032)
Table 58. Global VEGF Inhibitors Price (US$/Unit) by Type (2021–2026)
Table 59. Global VEGF Inhibitors Price (US$/Unit) by Type (2027–2032)
Table 60. Global VEGF Inhibitors Sales (K Units) by Application (2021–2026)
Table 61. Global VEGF Inhibitors Sales (K Units) by Application (2027–2032)
Table 62. Global VEGF Inhibitors Sales Market Share by Application (2021–2026)
Table 63. Global VEGF Inhibitors Sales Market Share by Application (2027–2032)
Table 64. Global VEGF Inhibitors Revenue (US$ Million) by Application (2021–2026)
Table 65. Global VEGF Inhibitors Revenue (US$ Million) by Application (2027–2032)
Table 66. Global VEGF Inhibitors Revenue Market Share by Application (2021–2026)
Table 67. Global VEGF Inhibitors Revenue Market Share by Application (2027–2032)
Table 68. Global VEGF Inhibitors Price (US$/Unit) by Application (2021–2026)
Table 69. Global VEGF Inhibitors Price (US$/Unit) by Application (2027–2032)
Table 70. Roche Company Information
Table 71. Roche Description and Business Overview
Table 72. Roche VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Roche VEGF Inhibitors Product
Table 74. Roche Recent Developments/Updates
Table 75. Novartis Company Information
Table 76. Novartis Description and Business Overview
Table 77. Novartis VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Novartis VEGF Inhibitors Product
Table 79. Novartis Recent Developments/Updates
Table 80. Coherus BioSciences Company Information
Table 81. Coherus BioSciences Description and Business Overview
Table 82. Coherus BioSciences VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Coherus BioSciences VEGF Inhibitors Product
Table 84. Coherus BioSciences Recent Developments/Updates
Table 85. Bayer Company Information
Table 86. Bayer Description and Business Overview
Table 87. Bayer VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Bayer VEGF Inhibitors Product
Table 89. Bayer Recent Developments/Updates
Table 90. Amneal Pharmaceuticals Company Information
Table 91. Amneal Pharmaceuticals Description and Business Overview
Table 92. Amneal Pharmaceuticals VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. Amneal Pharmaceuticals VEGF Inhibitors Product
Table 94. Amneal Pharmaceuticals Recent Developments/Updates
Table 95. Sanofi Company Information
Table 96. Sanofi Description and Business Overview
Table 97. Sanofi VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. Sanofi VEGF Inhibitors Product
Table 99. Sanofi Recent Developments/Updates
Table 100. Samsung Bioepis Company Information
Table 101. Samsung Bioepis Description and Business Overview
Table 102. Samsung Bioepis VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. Samsung Bioepis VEGF Inhibitors Product
Table 104. Samsung Bioepis Recent Developments/Updates
Table 105. Eli Lilly Company Information
Table 106. Eli Lilly Description and Business Overview
Table 107. Eli Lilly VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. Eli Lilly VEGF Inhibitors Product
Table 109. Eli Lilly Recent Developments/Updates
Table 110. Pfizer Company Information
Table 111. Pfizer Description and Business Overview
Table 112. Pfizer VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 113. Pfizer VEGF Inhibitors Product
Table 114. Pfizer Recent Developments/Updates
Table 115. Celltrion Healthcare Company Information
Table 116. Celltrion Healthcare Description and Business Overview
Table 117. Celltrion Healthcare VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 118. Celltrion Healthcare VEGF Inhibitors Product
Table 119. Celltrion Healthcare Recent Developments/Updates
Table 120. Amgen Company Information
Table 121. Amgen Description and Business Overview
Table 122. Amgen VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 123. Amgen VEGF Inhibitors Product
Table 124. Amgen Recent Developments/Updates
Table 125. Chengdu Kanghong Pharmaceutical Company Information
Table 126. Chengdu Kanghong Pharmaceutical Description and Business Overview
Table 127. Chengdu Kanghong Pharmaceutical VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 128. Chengdu Kanghong Pharmaceutical VEGF Inhibitors Product
Table 129. Chengdu Kanghong Pharmaceutical Recent Developments/Updates
Table 130. Key Raw Materials Lists
Table 131. Raw Materials Key Suppliers Lists
Table 132. VEGF Inhibitors Distributors List
Table 133. VEGF Inhibitors Customers List
Table 134. VEGF Inhibitors Market Trends
Table 135. VEGF Inhibitors Market Drivers
Table 136. VEGF Inhibitors Market Challenges
Table 137. VEGF Inhibitors Market Restraints
Table 138. Research Programs/Design for This Report
Table 139. Key Data Information from Secondary Sources
Table 140. Key Data Information from Primary Sources
Table 141. Authors List of This Report
List of Figures
Figure 1. Product Picture of VEGF Inhibitors
Figure 2. Global VEGF Inhibitors Market Value by Type (US$ Million), 2021–2032
Figure 3. Global VEGF Inhibitors Market Share by Type: 2025 & 2032
Figure 4. Monoclonal Antibodies Product Picture
Figure 5. Fusion Proteins Product Picture
Figure 6. Global VEGF Inhibitors Market Value by Application (US$ Million), 2021–2032
Figure 7. Global VEGF Inhibitors Market Share by Application: 2025 & 2032
Figure 8. Degenerative Eye Diseases
Figure 9. Cancer
Figure 10. Other
Figure 11. Global VEGF Inhibitors Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 12. Global VEGF Inhibitors Market Size (US$ Million), 2021–2032
Figure 13. Global VEGF Inhibitors Sales (K Units), 2021–2032
Figure 14. Global VEGF Inhibitors Average Price (US$/Unit), 2021–2032
Figure 15. VEGF Inhibitors Report Years Considered
Figure 16. VEGF Inhibitors Sales Share by Manufacturers in 2025
Figure 17. Global VEGF Inhibitors Revenue Share by Manufacturers in 2025
Figure 18. Top 5 and Top 10 Global VEGF Inhibitors Players: Market Share by Revenue in VEGF Inhibitors in 2025
Figure 19. VEGF Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 20. Global VEGF Inhibitors Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 21. North America VEGF Inhibitors Sales Market Share by Country (2021–2032)
Figure 22. North America VEGF Inhibitors Revenue Market Share by Country (2021–2032)
Figure 23. United States VEGF Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 24. Canada VEGF Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 25. Europe VEGF Inhibitors Sales Market Share by Country (2021–2032)
Figure 26. Europe VEGF Inhibitors Revenue Market Share by Country (2021–2032)
Figure 27. Germany VEGF Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 28. France VEGF Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. U.K. VEGF Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. Italy VEGF Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. Russia VEGF Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Asia Pacific VEGF Inhibitors Sales Market Share by Region (2021–2032)
Figure 33. Asia Pacific VEGF Inhibitors Revenue Market Share by Region (2021–2032)
Figure 34. China VEGF Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Japan VEGF Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. South Korea VEGF Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. India VEGF Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. Australia VEGF Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. China Taiwan VEGF Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Southeast Asia VEGF Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Latin America VEGF Inhibitors Sales Market Share by Country (2021–2032)
Figure 42. Latin America VEGF Inhibitors Revenue Market Share by Country (2021–2032)
Figure 43. Mexico VEGF Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Brazil VEGF Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Argentina VEGF Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Colombia VEGF Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Middle East and Africa VEGF Inhibitors Sales Market Share by Country (2021–2032)
Figure 48. Middle East and Africa VEGF Inhibitors Revenue Market Share by Country (2021–2032)
Figure 49. Turkey VEGF Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Saudi Arabia VEGF Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. UAE VEGF Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Global Sales Market Share of VEGF Inhibitors by Type (2021–2032)
Figure 53. Global Revenue Market Share of VEGF Inhibitors by Type (2021–2032)
Figure 54. Global VEGF Inhibitors Price (US$/Unit) by Type (2021–2032)
Figure 55. Global Sales Market Share of VEGF Inhibitors by Application (2021–2032)
Figure 56. Global Revenue Market Share of VEGF Inhibitors by Application (2021–2032)
Figure 57. Global VEGF Inhibitors Price (US$/Unit) by Application (2021–2032)
Figure 58. VEGF Inhibitors Value Chain
Figure 59. Channels of Distribution (Direct Vs Distribution)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
